AKT/mTORC pathway in antiphospholipid-related vasculopathy: A new player in the game

Lupus

Volumn 24, Issue 3, 2015, Pages 227-230

  Canaud, G ^a   Legendre, C ^a   Terzi, F ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; LIPOCORTIN 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NUCLEOLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID ANTIBODY; PROTEIN KINASE B; PROTEIN KINASE B BETA; RAPAMYCIN; TOLL LIKE RECEPTOR 4; TARGET OF RAPAMYCIN KINASE;

ALBUMINURIA; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; CELL ACTIVATION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE CELL; COMPLICATION; IMMUNOLOGY; METABOLISM; PARACRINE SIGNALING;

ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIAL CELLS; HUMANS; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; VASCULAR DISEASES;

EID: 84922625916     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315569336     Document Type: Review

References (32)

1. Alarcón-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol. 1989 ; 16: 762-767
2. Lepin EJ, Zhang Q, Zhang X, et al. Phosphorylated S6 ribosomal protein: A novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant. 2006 ; 6: 1560-1571
3. Lie JT. Vasculopathy in the antiphospholipid syndrome: Thrombosis or vasculitis, or both?. J Rheumatol. 1989 ; 16: 713-715
4. Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol. 1995 ; 26: 716-724
5. Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999 ; 10: 507-518
6. Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002 ; 13: 42-52
7. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004 ; 50: 2569-2579
8. Canaud G, Bienaimé F, Noël LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant. 2010 ; 10: 2051-2060
9. Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014 ; 371: 303-312
10. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999 ; 99: 2164-2170
11. Canaud G, Bienaimé F, Viau A, et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med. 2013 ; 19: 1288-1296
12. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006 ; 22: 159-168
13. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012 ; 335: 1638-1643
14. Canaud G, Knebelmann B, Harris PC, et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?. Am J Transplant. 2010 ; 10: 1701-1706
15. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol. 2011 ; 7: 330-339
16. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 ; 368: 1033-1044
17. Berchtold D, Piccolis M, Chiaruttini N, et al. Plasma membrane stress induces relocalization of Slm proteins and activation of TORC2 to promote sphingolipid synthesis. Nat Cell Biol. 2012 ; 14: 542-547
18. Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood. 2011 ; 117: 6383-6391
19. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2012 ; 119: 884-893
20. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell. 2007 ; 129: 1261-1274
21. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013 ; 13: 2179-2185
22. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993 ; 362: 801-809
23. Peiró C, Redondo J, Rodríguez-Martínez MA, Angulo J, Marín J, Sánchez-Ferrer CF. Influence of endothelium on cultured vascular smooth muscle cell proliferation. Hypertension. 1995 ; 25: 748-751
24. Milliat F, Francois A, Isoir M, et al. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: Implication in radiation-induced vascular damages. Am J Pathol. 2006 ; 169: 1484-1495
25. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991 ; 253: 1129-1132
26. Galvani S, Augé N, Calise D, et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant. 2009 ; 9: 2607-2614
27. Amano J, Ishiyama S, Nishikawa T, et al. Proliferation of smooth muscle cells in acute allograft vascular rejection. J Thorac Cardiovasc Surg. 1997 ; 113: 19-25
28. Shi C, Feinberg MW, Zhang D, et al. Donor MHC and adhesion molecules in transplant arteriosclerosis. J Clin Invest. 1999 ; 103: 469-474
29. Geraghty JG, Stoltenberg RL, Sollinger HW, Hullett DA. Vascular smooth muscle cells and neointimal hyperplasia in chronic transplant rejection. Transplantation. 1996 ; 62: 502-509
30. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med. 2001 ; 345: 93-97
31. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003 ; 349: 847-858
32. Boersema M, Katta K, Rienstra H, et al. Local medial microenvironment directs phenotypic modulation of smooth muscle cells after experimental renal transplantation. Am J Transplant. 2012 ; 12: 1429-1440